Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 9/7/2018 |
| Start Date: | March 2012 |
| End Date: | March 2032 |
| Contact: | Funda Meric-Bernstam, MD |
| Phone: | 713-792-6940 |
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential
participant.
The main goal of this study is to perform standardized testing of tumor tissue to learn which
genes are mutated (have changed) to provide personalized cancer therapy options to patients
at MD Anderson. Your doctor may be able to use testing information on your tumor to identify
clinical trials that may be most relevant to you.
Another goal of this laboratory research study is to learn how often different genes mutate
in patients with different cancers. Researchers will also use the information learned from
this study to develop a database of the different kinds of mutations in cancer-related genes.
Researchers also hope to better understand how mutations in cancer-related genes may affect a
patient's response to different therapies. Researchers can use this information to select
specific therapies for future patients that are more likely to be effective.
This is an investigational study.
Up to 12,000 patients will take part in this study. All will be enrolled at MD Anderson.
participant.
The main goal of this study is to perform standardized testing of tumor tissue to learn which
genes are mutated (have changed) to provide personalized cancer therapy options to patients
at MD Anderson. Your doctor may be able to use testing information on your tumor to identify
clinical trials that may be most relevant to you.
Another goal of this laboratory research study is to learn how often different genes mutate
in patients with different cancers. Researchers will also use the information learned from
this study to develop a database of the different kinds of mutations in cancer-related genes.
Researchers also hope to better understand how mutations in cancer-related genes may affect a
patient's response to different therapies. Researchers can use this information to select
specific therapies for future patients that are more likely to be effective.
This is an investigational study.
Up to 12,000 patients will take part in this study. All will be enrolled at MD Anderson.
Inclusion Criteria:
1. Patients must have histologically, radiographic, or cytologically documented cancer,
suspected glioma, sarcoma, melanoma or hematologic cancer. Patients with benign tumors
may also be consented at the discretion of the attending physician if molecular
profiling is felt to have potential clinical implications.
2. Patients must have the ability to understand and the willingness to sign a written
informed consent document.
3. Patients may be consented without confirming the amount and quality of archival
diagnostic or residual tissue available. However, research testing will only be
performed on patients who have sufficient archived diagnostic tissue or residual
tissue banked in one of the authorized tissue banks at MD Anderson available to
proceed with testing. The extent of testing may be modified based on amount of tissue
available. If any new tissue acquisition including a biopsy and/or surgical resection
etc. is being ordered for clinical care or another research study, or an operation is
being performed testing can be ordered on that sample.
4. cfDNA Cohort: Circulating cell-free DNA next generation sequencing (NGS) testing will
be performed with the CLIA-certified Guardant360 panel (or equivalent) for select
patients. This particular cohort of research collaboration will be supported by
Guardant Health, Inc. at no charge to MD Anderson. Patients who are being considered
for enrollment into clinical trials in the next 2 lines of therapy may be enrolled.
Selected patients may have cfDNA, circulating RNA /exosome/Circulating tumor cell
testing approaches performed on alternate platforms (eg Foundation ACT).
Exclusion Criteria:
We found this trial at
1
site
Houston, Texas 77030
Principal Investigator: Funda Meric-Bernstam, MD
Click here to add this to my saved trials
